What Is CJC-1295?

What CJC-1295 is

CJC-1295 is a synthetic peptide designed to copy and outlast the body’s own growth hormone-releasing hormone (GHRH). GHRH is the signal your brain sends to the pituitary gland telling it to release growth hormone (GH). The natural hormone works in seconds and is gone in minutes, which makes it useless as a practical medicine. CJC-1295 was built to solve that problem.

Chemically, it is based on the first 29 amino acids of GHRH — the shortest fragment that still fully activates the GHRH receptor — with four amino acid substitutions that make it resistant to the enzymes that normally break GHRH down. That modified backbone is the foundation of every version of the compound.

The single most important thing to understand about CJC-1295 is that “CJC-1295” actually refers to two meaningfully different molecules:

• CJC-1295 with DAC carries an extra chemical group (a “drug affinity complex,” or DAC) that latches covalently onto albumin, a protein in your blood. Tethered to albumin, the peptide is shielded from clearance and stays active for roughly six to eight days per dose, producing a long, sustained lift in GH and its downstream marker IGF-1.
• CJC-1295 without DAC lacks that linker. It is frequently sold under the name Mod GRF 1-29 (or “CJC-1295 no DAC”), clears in about 30 minutes, and produces only a brief burst of GH near the time of injection.

Those two are not subtle variants. They have different durations, different effects on GH secretion patterns, and different theoretical risk profiles. A great deal of confusion online — and many contradictory claims about CJC-1295 — comes from people discussing one version as if the research and behavior of the other applied. When the name appears without “DAC” or “no DAC” attached, it is genuinely ambiguous.

Note: CJC-1295 belongs to the same family as sermorelin and tesamorelin — all are GHRH analogs that bind the same pituitary receptor. They differ in half-life, evidence, and crucially in regulatory standing, which is why this site treats them as separate compounds rather than substitutes.

How it works

CJC-1295 does not contain growth hormone, and it is not synthetic GH. It is an upstream lever: instead of putting GH directly into the body, it nudges the pituitary to release more of its own.

The chain runs like this. CJC-1295 binds the GHRH receptor on the anterior pituitary, which prompts the gland to secrete growth hormone. Circulating GH then acts on the liver and other tissues to raise insulin-like growth factor 1 (IGF-1), the longer-lived hormone that mediates much of GH’s downstream activity and is the marker clinicians typically measure.

This indirect mechanism is often described as more “physiological” than injecting GH, because the pituitary still sits in the loop. That framing is only partly accurate, and the with-DAC version complicates it. The no-DAC form produces short, pulse-like GH spikes that resemble the body’s natural rhythm. The DAC form, by contrast, holds the GHRH signal switched on continuously for days, which produces a steadier, non-pulsatile elevation sometimes called a “GH bleed.” Whether the body’s natural pulsatile pattern matters for safety or for any real-world benefit is an open question — and one of several reasons the “it just helps your body do its own thing” pitch oversimplifies.

What the research actually shows

This is where honesty matters most, because the gap between what CJC-1295 has been shown to do and what it is marketed to do is large.

The defining human study is a Phase 1 trial by Teichman and colleagues, published in the Journal of Clinical Endocrinology & Metabolism in 2006. In a small group of healthy adults, single doses of the DAC version produced a clear, dose-dependent, and prolonged rise in blood GH and IGF-1 — IGF-1 stayed elevated for up to about eleven days. A companion study confirmed that GH secretion remained pulsatile even under continuous stimulation.

Read carefully, that trial establishes one thing: CJC-1295 reliably raises GH and IGF-1 levels in the bloodstream. It does not establish that those raised numbers translate into more muscle, less fat, faster injury recovery, better sleep, younger-looking skin, or any of the outcomes the compound is sold for. No published human trial tracked body composition, performance, or appearance. The elevated lab value is what researchers call a surrogate marker — a stand-in that might predict a benefit, but isn’t the benefit itself. The leap from “IGF-1 went up” to “you will look and feel different” is an inference, not a finding.

It is also worth knowing why the evidence stops there. CJC-1295 was developed in the mid-2000s by a company called ConjuChem (licensing technology from the University of Saskatchewan) as a candidate for growth hormone deficiency and wasting conditions. Early-phase trials were published, but the program was discontinued after a patient death in a separate Phase 2 lipodystrophy study. The death was ultimately deemed unrelated to the drug, but development never resumed, and CJC-1295 has lived in research and gray-market spaces ever since rather than progressing toward approval. So the thin evidence base is not a temporary state — it reflects a drug that was effectively abandoned before its real-world benefits were ever tested.

For a claim-by-claim breakdown of which purported benefits have any support and which are extrapolation, see CJC-1295 benefits: what the evidence shows.

What it’s used for

Officially, nothing — CJC-1295 has no approved use anywhere. Its original intended indications were growth hormone deficiency, lipodystrophy, and muscle-wasting conditions, none of which it reached the market for.

In practice, the compound circulates today for off-label and non-medical goals: recovery and “regeneration,” body recomposition, anti-aging, and sleep quality. It is very commonly paired with ipamorelin, a different kind of GH secretagogue that works through the ghrelin receptor; the idea is that the two pathways together produce a larger GH response. That stacking question — and why a “CJC-1295 review” is usually really a review of a combination — is covered in CJC-1295 vs ipamorelin.

None of these uses are validated by outcome trials in humans, and “studied for” is not the same as “shown to work for.” This site reports the mechanism and the marketing honestly without endorsing either.

Its US legal status in 2026

CJC-1295’s legal position in mid-2026 is genuinely unsettled, and it is easy to get wrong because it is changing and because it differs from the better-known peptides.

Here is the accurate picture as of this page’s date. In April 2026, the FDA removed a batch of previously restricted peptides from Category 2 of its 503A bulk-substances list — the category that had effectively banned licensed pharmacies from compounding them. CJC-1295 was among the substances cleared out of Category 2. That sounds like good news, and headlines treated it that way, but two qualifications matter enormously:

1. Removal from Category 2 is not the same as Category 1. None of these peptides were moved to Category 1 (the list of substances pharmacies may actually compound). They sit in a gap — no longer formally prohibited, not yet authorized — and most compounding pharmacies will not touch a substance in that gap without clearer FDA footing.
2. CJC-1295 is in a weaker position than the headline peptides. The compounds drawing the most attention — BPC-157, TB-500, MOTS-C, thymosin alpha-1, and others — are scheduled for formal review by the Pharmacy Compounding Advisory Committee (PCAC) at its meetings on July 23–24, 2026, the step that could move them toward legitimacy. CJC-1295 is not on that docket. As an investigational compound with a discontinued development program and prior unfavorable advisory treatment, it does not have a clear near-term path to compounding approval the way several other peptides do.

So the bottom line: CJC-1295 is not FDA-approved, has no clean legal compounding route in mid-2026, and is not scheduled for the review that might change that. A licensed provider could legally write a prescription, but a 503A pharmacy currently has no firm basis to fill it — which is why people seeking CJC-1295 so often end up in research-only (“not for human consumption”) gray-market channels of unknown purity and concentration.

Separately, CJC-1295 is banned in sport at all times. It appears on the World Anti-Doping Agency Prohibited List under the S2 category (growth hormone-releasing factors), so any competitive athlete subject to testing should treat it as off-limits regardless of its compounding status.

Because this is a fast-moving area, treat everything here as current as of the date at the top of the page and verify before relying on it. For the full regulatory story see the 2026 FDA peptide reclassification, and for the broader legal framework see Are peptides legal in the US?.

How people access it legally — and the cleaner alternatives

Legitimate access to any peptide therapy in the US runs through the same pipeline: a licensed provider evaluates you, and if appropriate writes a prescription that a compounding pharmacy fills. The problem for CJC-1295 specifically is the pharmacy step — given its status, most pharmacies decline to compound it, so the prescription often has nowhere clean to go. The mechanics of that route, and where it tends to break down, are covered in how to get CJC-1295 legally and CJC-1295 cost in the US.

This is also why the most useful thing to know about CJC-1295 may be its alternatives. Two other GHRH analogs in the same family have far cleaner standing:

• Sermorelin is also a GHRH analog, is more readily compoundable, and is generally cheaper. See what is sermorelin? and sermorelin vs CJC-1295.
• Tesamorelin (Egrifta) is an FDA-approved GHRH analog — approved for a specific condition, dispensed through normal pharmacy channels. See what is tesamorelin?.

For someone whose actual goal is supporting their own GH axis under medical supervision, a compound with a real regulatory pathway is worth understanding before pursuing one that has none.

The honest summary

CJC-1295 is a clever piece of pharmacology — a GHRH analog engineered for a long half-life — with a thin evidence base, a discontinued development history, and an uncertain legal status. It reliably raises GH and IGF-1 on a blood test; it has never been shown in humans to deliver the body-composition, recovery, or anti-aging outcomes it is sold for. In 2026 it has no clean legal route in the US and is not on the path several other peptides are now on. If you are researching it, the most valuable next steps are understanding what the evidence does and doesn’t support, and how it compares to the legal alternatives in its own family.

This page is educational and not medical advice. Decisions about any peptide should be made with a licensed clinician who can evaluate your individual situation.